Literature DB >> 15891403

The spectrum of multiple sclerosis: new lessons from pathology.

Wolfgang Brück1, Christine Stadelmann.   

Abstract

PURPOSE OF REVIEW: This review will focus on recent developments in multiple sclerosis (MS) pathology with particular emphasis on the patterns and mediators of lesion formation in MS, the mechanisms of oligodendrocyte and axon damage and the magnetic resonance imaging-pathological correlation of MS lesions. RECENT STUDIES: The inflammatory cascade in the MS plaque has been characterized in more detail, and other factors such as hypoxia-like injury or excitotoxicity, besides immunological effector mechanisms, have been found to play a role in MS pathogenesis. Cortical demyelination and mechanisms of neuroaxonal damage are discussed in detail. The radiological correlate of basic histopathologic findings is being approached with quantitative methods. Similar quantitative approaches are used in MS-gene expression studies that compare patterns of gene expression in different lesion areas.
SUMMARY: These studies will lead to better understanding of the pathogenesis of MS lesions and will hopefully identify new therapeutic targets to modulate inflammation, support remyelination and protect axons and neurons in MS.

Entities:  

Mesh:

Year:  2005        PMID: 15891403     DOI: 10.1097/01.wco.0000169736.60922.20

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  22 in total

Review 1.  Antioxidants in multiple sclerosis: do they have a role in therapy?

Authors:  Noel G Carlson; John W Rose
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  TGFbeta1 induces Jagged1 expression in astrocytes via ALK5 and Smad3 and regulates the balance between oligodendrocyte progenitor proliferation and differentiation.

Authors:  Yueting Zhang; Jingya Zhang; Kristina Navrazhina; Azeb Tadesse Argaw; Andleeb Zameer; Blake T Gurfein; Celia F Brosnan; Gareth R John
Journal:  Glia       Date:  2010-06       Impact factor: 7.452

Review 3.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

Review 4.  Mechanisms of neuronal damage in multiple sclerosis and its animal models: role of calcium pumps and exchangers.

Authors:  M P Kurnellas; K C Donahue; S Elkabes
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

Review 5.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

6.  Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination.

Authors:  Yueting Zhang; Azeb Tadesse Argaw; Blake T Gurfein; Andleeb Zameer; Brian J Snyder; Changhui Ge; Q Richard Lu; David H Rowitch; Cedric S Raine; Celia F Brosnan; Gareth R John
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-23       Impact factor: 11.205

7.  IL-11 regulates autoimmune demyelination.

Authors:  Blake T Gurfein; Yueting Zhang; Carolina B López; Azeb Tadesse Argaw; Andleeb Zameer; Thomas M Moran; Gareth R John
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

8.  Experimental Autoimmune Encephalomyelitis in Mice.

Authors:  Rachael L Terry; Igal Ifergan; Stephen D Miller
Journal:  Methods Mol Biol       Date:  2016

9.  Neuroprotective Effects of Melatonin on Experimental Allergic Encephalomyelitis Mice Via Anti-Oxidative Stress Activity.

Authors:  Ting Long; Yuan Yang; Ling Peng; Zuoxiao Li
Journal:  J Mol Neurosci       Date:  2018-02-15       Impact factor: 3.444

10.  Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.

Authors:  Z Khaleeli; J Sastre-Garriga; O Ciccarelli; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.